Otros idiomas Hyundai Bioscience Co., Ltd.

Acciones

A048410

KR7048410005

Productos personales

Precio de cierre Korea S.E. Otros sitios de cotización 11/07/2025			Variación 5 días	Varia. 1 de enero.
13.920,00 ^KRW	+28,65 %		+53,64 %	-1,35 %

15/05	Hyundai Bioscience Co., Ltd. publica los resultados financieros del primer trimestre finalizado el 31 de marzo de 2025.	CI
17/03	Hyundai Bioscience Co. presenta los resultados del ejercicio finalizado el 31 de diciembre de 2024	CI

Otros idiomas

Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	15/05
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	17/03
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	14/11
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD	18/09/24
Hyundai Bioscience USA Signs an MOU with the University of California San Diego to Conduct an Investigator-Initiated Trial to Evaluate the Efficacy of Xafty	18/09/24
Hyundai Bioscience Co., Ltd. to Conduct Phase 3 Clinical Trial for High-Risk Group of COVID-19 Patients with the Goal of Emergency Use Authorization	28/08/24
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	14/08/24
Hyundai Bioscience Co., Ltd. announced that it has received KRW 3 billion in funding	19/06/24
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 3 billion in funding	17/06/24
Hyundai Bioscience Co., Ltd. announced that it has received KRW 18 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank	20/05/24
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd..	20/05/24
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05/24
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 18 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank	16/05/24
Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil	25/04/24
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer	25/04/24
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer	22/04/24
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection	19/04/24
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim agreed to acquire 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd. for KRW 31 billion.	11/03/24
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03/24
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11/23
Vector Inc. completed the acquisition of additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd.	31/08/23
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22
Vector Inc. agreed to acquire additional 25.071429% stake in Vitabrid Japan Inc. from Hyundai Bioscience Co., Ltd. for KRW 13.7 billion.	25/08/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Hyundai Bioscience Co., Ltd.

Acciones

A048410

KR7048410005

Productos personales

Otros idiomas

Filtros